These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29600230)

  • 1. Standard-dose versus high-dose radiotherapy with concurrent chemotherapy in esophageal cancer: A prospective randomized study.
    Nayan N; Bhattacharyya M; Jagtap VK; Kalita AK; Sunku R; Roy PS
    South Asian J Cancer; 2018; 7(1):27-30. PubMed ID: 29600230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
    Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
    Suh YG; Lee IJ; Koom WS; Cha J; Lee JY; Kim SK; Lee CG
    Jpn J Clin Oncol; 2014 Jun; 44(6):534-40. PubMed ID: 24771865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
    Seung SK; Smith JW; Molendyk J; Bader SB; Phillips M; Regan J; Louie J; Soo E; Seligman M; Ruzich J; Skokan L; Ross HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):13-9. PubMed ID: 15726517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
    Reboul FL
    Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
    Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A multicenter randomized prospective study of concurrent chemoradiation with 60 Gy versus 50 Gy for inoperable esophageal squamous cell carcinoma].
    Xu YJ; Zhu WG; Liao ZX; Kong Y; Wang WW; Li JC; Huang R; He H; Yang XM; Liu LP; Sun ZW; He HJ; Bao Y; Zeng M; Pu J; Hu WY; Ma J; Jiang H; Liu ZG; Zhuang TT; Tan BX; Du XH; Qiu GQ; Zhou X; Ji YL; Hu X; Wang J; Ma HL; Zheng X; Huang J; Liu AW; Liang XD; Tao H; Zhou JY; Liu Y; Chen M
    Zhonghua Yi Xue Za Zhi; 2020 Jun; 100(23):1783-1788. PubMed ID: 32536123
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent FP (5-fluorouracil, cisplatin) Chemoradiotherapy for Patients with Esophageal Cancer.
    Kim MO; Hong ES; Chai JY; Leem JM; You IY; Kim WD; Park WY; Kim ST; Lee KH
    Cancer Res Treat; 2003 Aug; 35(4):330-4. PubMed ID: 26680955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study.
    Zhao KL; Shi XH; Jiang GL; Yao WQ; Guo XM; Wu GD; Zhu LX
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1014-20. PubMed ID: 15990003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
    Singh AK; Lockett MA; Bradley JD
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.
    Chen B; Li Q; Li Q; Qiu B; Xi M; Liu M; Hu Y; Zhu Y
    Oncologist; 2020 Apr; 25(4):308-e625. PubMed ID: 31880371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula.
    Nishimura Y; Suzuki M; Nakamatsu K; Kanamori S; Yagyu Y; Shigeoka H
    Int J Radiat Oncol Biol Phys; 2002 May; 53(1):134-9. PubMed ID: 12007951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.
    Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report.
    Gaspar LE; Qian C; Kocha WI; Coia LR; Herskovic A; Graham M
    Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):593-9. PubMed ID: 9112458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
    Minsky BD; Pajak TF; Ginsberg RJ; Pisansky TM; Martenson J; Komaki R; Okawara G; Rosenthal SA; Kelsen DP
    J Clin Oncol; 2002 Mar; 20(5):1167-74. PubMed ID: 11870157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
    Kleinberg L; Knisely JP; Heitmiller R; Zahurak M; Salem R; Burtness B; Heath EI; Forastiere AA
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):328-34. PubMed ID: 12738305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.